dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Isakoff, S. J. |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Molife, L. R. |
dc.contributor.author | Soria, J.-C. |
dc.contributor.author | Vogelzang, N. J. |
dc.contributor.author | Argilés Martinez, Guillem |
dc.contributor.author | Cervantes, Andrés |
dc.date.accessioned | 2021-09-13T12:15:56Z |
dc.date.available | 2021-09-13T12:15:56Z |
dc.date.issued | 2020-05 |
dc.identifier.citation | Isakoff SJ, Tabernero J, Molife LR, Soria JC, Cervantes A, Vogelzang NJ, et al. Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. Ann Oncol. 2020 May;31(5):626-33. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/6308 |
dc.description | Inhibidor d'AKT; Càncer avançat; Fase I |
dc.description.sponsorship | This work was supported by Genentech, Inc., a member of the Roche Group, and F. Hoffmann-La Roche Ltd. (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;31(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Quimioteràpia |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2020.02.007 |
dc.subject.decs | neoplasias |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2020.02.007 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Isakoff SJ] Department of Hematology/Oncology, Massachusetts General Hospital, Boston, USA. [Tabernero J, Argilés G] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Molife LR] Drug Development Unit, The Royal Marsden and Institute of Cancer Research, Sutton, UK. [Soria JC] Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, and Université Paris-Sud, Orsay, France. [Cervantes A] CIBERONC, Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. [Vogelzang NJ] Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA |
dc.identifier.pmid | 32205017 |
dc.identifier.wos | 000529333600010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |